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Structured Summary 38 
Background: 39 
The licensed intravenous acetylcysteine regimen for treating paracetamol overdose 40 
in most countries uses three separate infusions over 21 hours. This complex 41 
regimen, requiring different infusion concentrations and rates, has been associated 42 
with administration errors. The aim was to assess the extent of administration 43 
delays occurring during this acetylcysteine regimen. 44 
Method: 45 
A 6-month retrospective observational study was conducted at three English 46 
teaching hospitals with clinical toxicology services from October 2014. Patients 47 
aged 16-years and over treated with intravenous acetylcysteine for paracetamol 48 
overdose were included. The start times for infusions were recorded and the delays 49 
compared to the prescribed infusion times were calculated. Anaphylactoid 50 
reactions, intravenous cannula problems, overdose intent and smoking status were 51 
recorded to assess their contribution to delays. 52 
Results: 53 
From 263 cases identified, 198 met study inclusion criteria. The median time 54 
between the start of infusions 1 and 3 was delayed from the intended 5 hours by a 55 
median (IQR) of 90 (50-163) minutes, with 135 (68%) cases delayed by more than 56 
one hour.  Significantly longer delays were observed in patients with anaphylactoid 57 
reactions (median delay 267 (217-413) minutes, n=8) and accidental / supra-58 
therapeutic overdose (median delay 170 (95-260) minutes, n=29). There were no 59 
significant differences between smokers and non-smokers and for patients with 60 
intravenous cannula problems.   61 
Conclusion: 62 
 4 
Long delays were identified during the three-infusion acetylcysteine regimen for 63 
the treatment of paracetamol overdose. Delays were of clinical significance and 64 
could lead to periods of sub-therapeutic plasma acetylcysteine concentrations and 65 
potentially avoidable hepatotoxicity, as well as delaying hospital discharge. 66 
 67 
 68 
 69 
 70 
What is already known about this subject: 71 
- The licensed intravenous acetylcysteine regimen for treating paracetamol 72 
overdose in most countries uses three separate infusions administered 73 
over 21 hours.  74 
- This complex regimen, requiring different infusion concentrations and 75 
rates, has been associated with administration errors. 76 
 77 
What this study adds: 78 
- Long delays were identified during the three-infusion acetylcysteine 79 
regimen for the treatment of paracetamol overdose. 80 
- Delays could increase the length of hospital stay and were of clinical 81 
significance and could lead to sub-therapeutic plasma acetylcysteine 82 
concentrations and potentially avoidable hepatotoxicity. 83 
 84 
 85 
 86 
 87 
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Introduction  88 
In most countries, the licensed intravenous acetylcysteine regimen for treating 89 
paracetamol (acetaminophen) overdose involves three separate infusions given 90 
over a total of 21 hours. The first infusion is administered over 1 hour, the 91 
second over 4 hours and the third (and any subsequent) infusions over 16 hours. 92 
[1] Each infusion is prepared by adding the required volume of acetylcysteine 93 
solution to three different volume infusion bags of 5% dextrose or 0.9% sodium 94 
chloride. There should ideally be no delay in between the infusions to minimise 95 
treatment duration and length of stay, whilst providing maximal hepatic 96 
protection from the toxic metabolite of paracetamol, N-acetyl-p-benzoquinone 97 
imine (NAPQI). Treatment is usually started in the Emergency Department and 98 
continued on an admission/medical/observation ward.  99 
 100 
The complexity of the regimen, with the requirement for three different infusion 101 
concentrations and rates has been associated with administration errors. [2,3,4] 102 
In a US retrospective chart review, Hayes and colleagues found medication 103 
errors in the treatment of 33% of 221 patients treated with intravenous 104 
acetylcysteine for paracetamol overdose. The most frequent error, in 18.6% 105 
cases, was the interruption of treatment by more than one hour; in addition, 106 
incorrect infusion rates were seen in 5% of cases (the authors did not record 107 
whether administration was too fast or slow). [3] In a Malaysian audit of 236 108 
patients treated with acetylcysteine for paracetamol poisoning, interruptions in 109 
treatment of more than one hour were seen in fewer cases (5.5%) than in the US 110 
study but infusion rate errors were recorded in more (37.3%). [4] In the US 111 
study the same three-infusion regimen was in place as currently used in the UK.  112 
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In the Malaysian study the three-infusion regimen was the same apart from the 113 
initial infusion being administered over 15 minutes, rather than 1 hour, as was 114 
routine in the UK until 2012.  115 
 116 
Consistent with these US and Malaysian studies, our own experience is that the 117 
time taken for acetylcysteine infusions to be completed is often longer than 118 
expected. The aim of this study was to assess the extent of delays during the 119 
administration of the three-infusion intravenous acetylcysteine regimen in three 120 
English hospitals, and to understand when these delays occurred during 121 
treatment. 122 
 123 
Methods 124 
A retrospective observational study was conducted at three English teaching 125 
hospitals with clinical toxicology services. Patients aged 16-years and over, 126 
treated with intravenous acetylcysteine for paracetamol overdose between 1st 127 
October 2014 and 31st March 2015 were identified from the clinical toxicology 128 
databases used at the three hospitals. Patients were excluded if any of the start 129 
times for the three infusions were not recorded or if treatment was stopped 130 
prior to the start of the third infusion.  131 
 132 
In addition to basic demographic data (age/sex), the start/stop times for all 133 
infusions were recorded and delays to treatment (in minutes) were calculated 134 
comparing times recorded for administration to the predicted times based on the 135 
prescribed infusion times. This was recorded for: i) the start of the first and 136 
second infusions; ii) the start of the second and third infusions; and iii) the start 137 
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of the first and third infusions.  The primary outcome measure was the delay 138 
between the start of the first and the start of the third infusion. When 139 
documented, infusion stop times were also recorded and the total delays to 140 
complete all three infusions were calculated. In addition, smoking status, 141 
overdose intent (intentional or accidental/supra-therapeutic overdose), 142 
anaphylactoid reactions (defined as documented anaphylactoid reaction, 143 
bronchospasm, rash, swelling, or reaction requiring treatment with 144 
antihistamines and /or steroids) and intravenous cannula related problems 145 
(documentation that an intravenous cannula was misplaced or stopped working) 146 
were recorded to assess if these contributed to any delays that occurred.  147 
 148 
The data were collated in an Excel spreadsheet and analysed using Excel and 149 
SPSS Statistics (version 21, IBM).  The impact of the additional factors was 150 
assessed using Mann-Whitney U tests. Results from the three hospitals were 151 
compared using Kruskal-Wallis tests. 152 
 153 
Data for audit of the management of paracetamol overdose are routinely and 154 
prospectively collected on databases held within the clinical toxicology units at 155 
the study centres and these are approved by the local data protection officers / 156 
Caldicott Guardians.  157 
 158 
Results 159 
There were 263 cases identified during the 6-month study period at the three 160 
hospitals: 86 in London (15 excluded), 108 in Newcastle (31 excluded) and 69 in 161 
York (19 excluded). Sixty-five cases were excluded because treatment was 162 
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discontinued before the start of the third infusion (19 cases), the start times for 163 
all three infusions were not documented (25 cases), or the prescription charts or 164 
notes were missing (21 cases). Thus 198 cases were included in the analysis with 165 
a mean ± SD age of 33.6 ±15.9 years and 114 (57.5%) were female. Those 166 
excluded had a mean ± SD age of 32.8 ±13 years and 54.0% were female.  167 
 168 
The median (IQR) delay compared to the 5 hour interval intended between the 169 
start of infusions 1 and 3 was 90 (50-163) minutes. The median delay compared 170 
to the 1 hour interval intended between the start of infusions 1 and 2 was 25 171 
(10-60) minutes and compared to the 4 hour interval intended between the start 172 
of infusion 2 and 3 was 50 (15-104) minutes. There was a delay of more than one 173 
hour compared to the prescribed times between the start of infusions 1 and 3 in 174 
135 (68.2%) cases, of more than 2 hours in 78 (39.4%) cases and of more than 3 175 
hours in 41 (20.7%) cases. In four cases (2.0%) there were delays of more than 176 
10 hours compared to prescribed times between the start of infusions 1 and 3.  177 
 178 
Smoking status, anaphylactoid reactions and cannula problems were recorded at 179 
the hospitals in London and Newcastle but not York. Comparisons between 180 
smokers and non-smokers, intentional and accidental/supra-therapeutic 181 
overdoses and those with/without cannula problems or anaphylactoid reactions 182 
are shown in table 1. Smoking status had no significant effect on the delays but 183 
patients with accidental / supra-therapeutic overdoses, anaphylactoid reactions 184 
experienced significantly longer delays.  185 
 186 
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Adverse effects were recorded in London and Newcastle. Eight (5.4%) patients 187 
had anaphylactoid reactions and 28 (18.9%) experienced nausea and/or 188 
vomiting. The median (IQR) delay between the start of infusions 1 and 3 189 
compared to prescribed times for patients with anaphylactoid reactions was 267 190 
(217–413) minutes compared to 90 (53-155) minutes for patients without 191 
anaphylactoid reactions (n=147). Delays for patients with anaphylactoid 192 
reactions were 188 (140-230) minutes between the start of infusions 1 and 2 193 
and 60 (26-93) minutes between the start of infusions 2 and 3. At the two 194 
centres where adverse reactions were recorded, 34 (23.0%) patients 195 
experienced delays of more than 3 hours and 6 (17.6%) of these had 196 
anaphylactoid reactions. For patients without anaphylactoid reactions, the 197 
median (IQR) delay from the start of infusion 1 to infusion 3 remained 198 
significantly longer for those with accidental / supra-therapeutic overdose; 155 199 
(90-255) minutes compared to 85 (50-142) minutes for intentional overdoses 200 
(p=0.0008).  201 
 202 
The stop time for the third infusion was recorded in only 36 (18.2%) cases.  For 203 
these patients the median (IQR) delay between the start of infusion 1 and the 204 
end of infusion 3 was 175 (103-300) minutes. The median (IQR) delay compared 205 
to the 16 hour interval intended from the start of infusion 3 to the end of 206 
infusion 3 for this group was 60 (20-139) minutes. The median (IQR) delay 207 
between the start of infusions 1 and 3 for this group was 75 (45-152) minutes, 208 
which was not significantly different to the 90 minute delay observed in the 209 
whole cohort.  210 
 211 
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The delays compared to prescribed times in each of the three hospitals are 212 
demonstrated in figure 1. Comparing the three hospitals, there was a median 213 
(IQR) delay between the start of infusions 1 and 3 of 140 (67-197) minutes in 214 
London, 75 (40-130) minutes in Newcastle and 90 (45-145) minutes in York.  215 
Delays in Newcastle were significantly shorter than in London (p=0.0015). 216 
Differences between delays comparing Newcastle and York and London and 217 
York were not significant.  218 
 219 
Discussion 220 
A delay of more than one hour compared to prescribed infusion times between 221 
the start of infusions 1 and 3 occurred for over two-thirds of patients in this 222 
study.  For the group with total infusion times recorded, further delays occurred 223 
both between each infusion and during the infusions. This suggests the delays 224 
result from both time preparing and instigating infusions, and during infusions.     225 
 226 
The impact of delays in administration on plasma concentrations of 227 
acetylcysteine and outcomes has not previously been reported, but Hayes and 228 
colleagues [3] suggested that delays of more than one hour should be considered 229 
potentially significant based on the elimination half life for acetylcysteine of 5.7 230 
hours found by Prescott et al. [5] in a pharmacokinetic study of the three 231 
infusion regimen. The extent of the delays identified could lead to potentially 232 
avoidable hepatotoxicity. However, it is not clear at what point the duration of 233 
the delay might lead to an increased risk of liver injury.  234 
 235 
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Infusion delays prolong the time that patients are admitted to hospital, increase 236 
costs and increase acute medical inpatient bed occupancy. Most patients (85% of 237 
this cohort) are treated following intentional paracetamol overdoses and 238 
prolonging their stay as a medical inpatient delays psychiatric / psychosocial 239 
assessment. 240 
 241 
Anaphylactoid reactions and intravenous cannula related problems contributed 242 
to delays in treatment but there were important delays for patients with no 243 
documented evidence of either of these complications. The incidence of 244 
anaphylactoid reactions in this study was 5.2%, which is lower than previously 245 
reported. [6,7,8,9] The incidence of intravenous cannula related problems was 246 
also lower than expected; these included removal, difficulty re-inserting and 247 
blockages in tubing. The retrospective data collection and reliance on 248 
documentation of anaphylactoid reactions and cannula problems in the medical 249 
notes may have resulted in under-reporting of these events.  250 
 251 
It was expected that patients leaving the ward to smoke might delay infusions 252 
more in smokers compared to non-smokers. However, smoking status had no 253 
effect on the delays. This may be because of the use of nicotine replacement in 254 
hospital inpatients.  255 
 256 
Delays were surprisingly significantly longer for patients presenting following 257 
accidental overdose compared to those with intentional overdoses. Patients with 258 
lower serum paracetamol concentrations are at greater risk of anaphylactoid 259 
reactions. [9] Patients with accidental / supra-therapeutic overdose often 260 
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present with lower serum paracetamol concentrations and are therefore 261 
potentially, a higher rate of occurrence of adverse reactions in this group could 262 
have contributed to their delays. However, delays remained longer in those that 263 
did not suffer anaphylactoid reactions, suggesting that other factors were 264 
important. It is possible that less severe reactions occurred for some patients 265 
and delayed infusions but this was not documented. Patients presenting 266 
following intentional overdoses frequently require close observation by staff and 267 
occasionally 1:1 observation by a mental health nurse. It is possible that the need 268 
for increased observation results in earlier recognition of acetylcysteine 269 
infusions finishing or problems with the infusions. Delays could potentially have 270 
been caused by waiting for repeat blood test results in deciding on the treatment 271 
courses for patients with staggered overdoses. However, local practice is to 272 
continue infusions until results are available (up until the end of the third 273 
infusion). 274 
 275 
Patients are usually transferred between departments at least once during their 276 
treatment course with acetylcysteine (most often between the emergency 277 
department and admission / medical / observation wards). The prolonged 278 
nature of the infusion involves handover of care between medical and nursing 279 
staff working in shifts. There may have been delays starting the next infusion 280 
while care is handed over between teams.  281 
 282 
Electronic infusion pumps are used to set infusion times. Therefore, 283 
theoretically, administration during infusions should not be delayed. However, 284 
infusion rate errors were noted in previous US and Malaysian studies on 285 
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acetylcysteine errors, although the exact nature of these errors was not clear.  286 
[3,4] Infusion pump calibrations were not assessed as part of this study. 287 
Discrepancies in the volumes in infusion could also contribute to delays. From 288 
personal communication with the manufacturer for the infusion bags used in 289 
London, the range of volumes in infusion bags were: 265–277mL (250mL bag), 290 
520-540mL (500mL bag) and 1025-1069mL (1000mL bag). Infusion times 291 
would be longer than expected if the infusion pumps were not set to account for 292 
these volumes and the volume of acetylcysteine added. However, there is a small 293 
volume of infusion fluid left in tubing and the infusion bag on completion of the 294 
infusion. These factors could contribute to short delays but would not result in 295 
the magnitude of delays found in this study. 296 
 297 
With stop times inadequately recorded in this study it is difficult to ascertain 298 
whether the delays are mostly occurring between infusions or during infusions. 299 
Our study demonstrated longer delays between the start of infusions 2 and 3 300 
compared to between the start of infusions 1 and 2, (in view of the longer 301 
duration of infusion 2) this suggests that delays are likely also occurring during 302 
the infusions rather than simply delays in starting the next infusion. Delays for 303 
patients with anaphylactoid reactions were longer between the start of infusions 304 
1 and 2 compared to between the start of infusions 2 and 3. This suggests that 305 
reactions may have been more frequent or severe during the first infusion 306 
compared to the second infusion. However, there were few patients with 307 
documented anaphylactoid reactions limiting the interpretation of this finding.  308 
 309 
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Acetylcysteine dosing tables produced by the MHRA, as part of the 2012 changes 310 
to UK guidelines on the treatment of paracetamol overdose, were used in all 311 
three centres. [1] These were produced with the aim of simplifying drug 312 
calculations and preparation; and providing the volume of acetylcysteine to be 313 
added for each infusion.  314 
 315 
Delay to initiation of acetylcysteine is another aspect of the treatment of 316 
paracetamol overdose where delays occur. This was not assessed in this study. 317 
The RCEM Paracetamol Overdose Clinical Audit 2013-2014 found that for 318 
patients presenting less than 8 hours from ingestion 50% received treatment 319 
with acetylcysteine within the recommended 8 hours of ingestions. [10] For 320 
patients presenting more than 8 hours after ingestion 80% of Emergency 321 
Departments did not administer acetylcysteine to any patients within the 322 
recommended 1 hour. [10] In a single centre audit, Pettie and colleagues found 323 
that for patients presenting either 8-24 hours post-ingestion or with staggered 324 
overdose and considered at risk of hepatotoxicity, 12% had acetylcysteine 325 
started within 90 minutes of arrival and this improved to 61% following the 326 
introduction of an integrated care pathway. [11] Improvements were also made 327 
to blood sampling and treatment decisions and prescription errors were 328 
reduced.  329 
 330 
To improve administration times the problem should be highlighted to those 331 
treating patients with intravenous acetylcysteine. During nursing and medical 332 
handovers the prescribed planned start and finish times for each infusion could 333 
be reviewed and infusion times monitored. All three centres in this study 334 
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currently use paper prescription charts of acetylcysteine - electronic prescribing 335 
systems could aid this process, including medication administration timing 336 
reminders or alerts to notify staff that there has been a delay in the infusion time. 337 
Electronic prescribing should also improve documentation of infusion times and 338 
times will be standardised / co-ordinated rather than relating to individual 339 
watches / clocks. 340 
 341 
Preparation of the second and third infusions immediately after the first has 342 
started, so they can be changed more quickly, could reduce delays in between 343 
infusions. Improved documentation of infusion stop times would help to identify 344 
which steps are associated with the longest delays and determine the extent of 345 
the delays for the full three infusions. If a delay is recognised, the infusion rate 346 
could be increased to target the planned infusion stop time. This is unlikely to 347 
increase adverse effects because these occurred at similar rates when the first 348 
infusion was previously administered over 15 minutes in the UK. [12]  349 
 350 
Recently, a number of alternative two infusion acetylcysteine regimens have 351 
been trialled, and these are associated with a lower incidence of adverse effects. 352 
[13,14,15,16,17] By reducing the number of infusions required, these are also 353 
likely to reduce delays in infusions. The SNAP regimen used by Bateman and 354 
colleagues [13] is shorter (over 12 hours) and therefore would significantly 355 
reduce total infusion times irrespective of the delays. However, despite 356 
promising initial results, further evidence is required to demonstrate the efficacy 357 
of this shorter regimen.  358 
 359 
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Limitations 360 
The study relied on retrospective data collection for identifying infusion start 361 
times; it is possible these may not reflect the actual start time of the infusions. 362 
Data collection was from handwritten medical notes, with times recorded from 363 
non-standardised clocks. Due to inadequate recording of stop times the delays 364 
reported are in most cases between the start of the first and third infusions and 365 
therefore will under represent the extent of total delays. Markers of 366 
hepatotoxicity, paracetamol concentrations and patient outcomes were not 367 
recorded in this study. 368 
 369 
Conclusion 370 
Long delays were identified during the three-infusion acetylcysteine regimen for 371 
the treatment of paracetamol overdose. Delays will increase the length of 372 
hospital stay and were of clinical significance and could lead to sub-therapeutic 373 
plasma acetylcysteine concentrations and potentially avoidable hepatotoxicity. 374 
Early preparation of infusions, adjusting infusion times to compensate for delays 375 
and novel regimens with two infusions are options that may reduce delays.  376 
 377 
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Table & Figure Legends 385 
 386 
Table 1: Comparisons between different groups for median delays between the start of infusions 1 to 387 
3. Groups were compared with the Mann-Whitney U test. Note: smoking status, anaphylactoid 388 
reactions and cannula problems were not recorded for all patients.  389 
 390 
Figure 1: The delays in minutes compared to prescribed times from the start of infusion 1 to the 391 
start of infusion 3 for the three hospitals. 392 
 393 
References 394 
1. Commission on Human Medicines. Paracetamol overdose: new guidance on the use of 395 
intravenous acetylcysteine. 396 
http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/ho397 
me/groups/pl-p/documents/drugsafetymessage/con178654.pdf (accessed 10 February 398 
2016) 399 
2. Ferner RE, Langford NJ, Anton C, Hutchings A, Bateman DN, Routledge PA. Random and 400 
systematic medication errors in routine clinical practice: a multicentre study of infusions, 401 
using acetylcysteine as an example. Br J Clin Pharmacol 2001; 52: 573-577. 402 
3. Hayes BD, Klein-Schwartz W, Doyon S. Frequency of medication errors with intravenous 403 
acetylcysteine for acetaminophen overdose. Annals of Pharmacotherapy 2008; 42(6): 766-70. 404 
4. Au V, Zakaria MI. A study on the medication errors in the administration of N-acetylcysteine 405 
for paracetamol overdose patients in Malaysia. Hong Kong Journal of Emergency Medicine 406 
2014; 21(6): 362-367. 407 
5. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The disposition and kinetics of 408 
intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 409 
1989;37:501-6. 410 
6. Yamamoto T, Spencer T, Dargan PI, Wood DM. Incidence and management of N-411 
acetylcysteine-related anaphylactoid reactions during the management of acute paracetamol 412 
overdose. Eur J Emerg Med 2014; 21(1): 57-60. 413 
 18 
7. Schmidt LE. Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in 414 
the treatment of paracetamol overdose. Clin Toxicol (Phila) 2013; 51(6): 467-72. 415 
8. Lynch RM, Robertson R. Anaphylactoid reactions to intravenous N-acetylcysteine: a 416 
prospective case controlled study. Accid Emerg Nurs 2004; 12(1): 10-15. 417 
9. Pakravan N, Waring WS, Sharma S, Ludlam C, Megson I, Bateman DN. Risk factors and 418 
mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clin 419 
Toxicol (Phila) 2008; 46(8): 697-702. 420 
10. Royal College of Emergency Medicine. Paracetamol Overdose Clinical Audit 2013-2014. 421 
https://secure.rcem.ac.uk/CEM/document?id=8120 (accessed 20 June 2016) 422 
11. Pettie JM, Dow MA, Sandilands EA, Thanacoody HKR, Bateman DN. An integrated care 423 
pathway improves the management of paracetamol poisoning. Emerg Med J 2012; 29: 482-424 
486. 425 
12. Bateman DN, Carroll R, Pettie J, Yamamoto T, Elamin ME, Peart L, Dow M, Coyle J, Cranfield 426 
KR, Hook C, Sandilands EA, Veiraiah A, Webb D, Gray A, Dargan PI, Wood DM, Thomas SH, 427 
Dear JW, Eddleston M. Effect of the UK’s revised paracetamol poisoning management 428 
guidelines on admissions, adverse reactions and costs of treatment. Br J Clin Pharmacol 429 
2014; 78(3): 610-618. 430 
13. Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M, Sandilands EA, Coyle J, 431 
Cooper JG, Rodriguez A, Butcher I, Lewis SC, Vliegenthart AD, Veiraiah A, Webb DJ, Gray A. 432 
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol 433 
poisoning: a randomised controlled trial. Lancet 2014; 383: 697-704. 434 
14. Wong A, Graudins A. A Simplification of the standard three-bag intravenous acetylcysteine 435 
regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. 436 
Clin Toxicol (Phila) 2016; 54(2): 115-119.  437 
15. Isbister GK, Downes MA, McNamara K, Berling I, Whyte IM, Page CB. A prospective 438 
observational study of a novel 2-phase infusion protocol for the administration of 439 
acetylcysteine in paracetamol poisoning. Clin Toxicol (Phila) 2016; 54(2): 120-126. 440 
16. Bateman DN, Dear JW, Thomas SH. New regimens for intravenous acetylcysteine, where are 441 
we now? Clin Toxicol (Phila) 2016; 54(2): 75-78.  442 
 19 
17. Waring WS. Novel acetylcysteine regimens for treatment of paracetamol overdose. Ther Adv 443 
Drug Saf. 2012; 3(6): 305-315. 444 
 445 
